1 Autoantigen profiling reveals a shared post-COVID signature in fully recovered and Long

2 COVID patients

- 3
- 4 Aaron Bodansky,¹ Chung-Yu Wang,² Aditi Saxena, ² Anthea Mitchell, ² Saki Takahashi,³ Khamal
- 5 Anglin,⁴ Beatrice Huang,³ Rebecca Hoh,³ Scott Lu,⁴ Sarah A. Goldberg,⁴ Justin Romero,³ Brandon
- 6 Tran,³ Raushun Kirtikar,³ Halle Grebe,³ Matthew So,³ Bryan Greenhouse,³ Matthew S.
- 7 Durstenfeld,⁵ Priscilla Y. Hsue,⁵ Joanna Hellmuth,⁶ J. Daniel Kelly,⁴ Jeffrey N. Martin,⁴ Mark S.
- 8 Anderson,^{7,8} Steven G. Deeks,³ Timothy J. Henrich,⁹ Joseph L. DeRisi,² Michael J. Peluso³
- 9
- 10 1 Division of Pediatric Critical Care Medicine, University of California, San Francisco, San
- 11 Francisco, CA, USA
- 12 2 Chan Zuckerberg Biohub, San Francisco, CA, USA
- 13 3 Division of HIV, Infectious Diseases, and Global Medicine, University of California, San
- 14 Francisco, San Francisco, CA, USA
- 15 4 Department of Epidemiology and Biostatistics, University of California, San Francisco, San
- 16 Francisco, CA, USA
- 17 5 Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA
- 18 6 Department of Neurology University of California, San Francisco, San Francisco, CA, USA
- 19 7 Diabetes Center, University of California, San Francisco, San Francisco, CA, USA
- 20 8 Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
- 21 9 Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA,
- 22 USA
- 23
- 24 Corresponding Author: Aaron Bodansky, MD
- 25 (PhIP-Seq Questions) Division of Pediatric Critical Care Medicine

medRxiv preprint doi: https://doi.org/10.1101/2023.02.06.23285532; this version posted February 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.		
26		University of California, San Francisco
27		San Francisco, CA, USA
28		Email: aaron.bodansky@ucsf.edu
29		
30	Alternate Corresponding Author:	Michael Peluso, MD
31	(Cohort Questions)	Division of HIV, Infectious Diseases, and Global Medicine
32		University of California, San Francisco
33		San Francisco, CA, USA
34		Email: michael.peluso@ucsf.edu
35		
36	Keywords: SARS-CoV-2, COVIE	0-19, post-acute sequelae of SARS-CoV-2 infection (PASC),

37 Long COVID, autoreactivity, autoimmunity, autoantigen

38 ABSTRACT

39 Some individuals do not return to baseline health following SARS-CoV-2 infection, leading to a 40 condition known as Long COVID. The underlying pathophysiology of Long COVID remains unknown. Given that autoantibodies have been found to play a role in severity of COVID infection 41 and certain other post-COVID sequelae, their potential role in Long COVID is important to 42 43 investigate. Here we apply a well-established, unbiased, proteome-wide autoantibody detection 44 technology (PhIP-Seq) to a robustly phenotyped cohort of 121 individuals with Long COVID, 64 45 individuals with prior COVID-19 who reported full recovery, and 57 pre-COVID controls. While a distinct autoreactive signature was detected which separates individuals with prior COVID 46 infection from those never exposed to COVID, we did not detect patterns of autoreactivity that 47 48 separate individuals with Long COVID relative to individuals fully recovered from SARS-CoV-2 infection. These data suggest that there are robust alterations in autoreactive antibody profiles 49 50 due to infection; however, no association of autoreactive antibodies and Long COVID was 51 apparent by this assay.

53 BACKGROUND

Some individuals do not fully return to baseline health following SARS-CoV-2 infection and experience ongoing morbidity following the acute phase of COVID-19 (1, 2). There is now intense interest in determining the underlying mechanisms of Long COVID, one type of post-acute sequelae of SARS-CoV-2 infection (PASC) characterized by symptoms that newly developed or worsened following infection that cannot be clearly attributed to another cause (3). Immune dysregulation, including the generation of antibodies against self antigens, has been suggested as one potential driver of Long COVID that warrants further investigation (4, 5).

62 Acute SARS-CoV-2 infection is associated with the generation of autoreactive antibodies,

63 particularly among individuals with severe disease requiring hospitalization (6–8). For example,

one study of 147 individuals hospitalized with COVID-19 found that autoantibodies associated with

65 connective tissue diseases and anti-cytokine antibodies were identified in 50% of samples, and

66 tracked with the humoral response to SARS-CoV-2 infection (7). Furthermore, multiple studies

67 have described the contribution of likely pre-existing anti-interferon antibodies to vaccine

68 breakthrough infections and severe manifestations of COVID-19, including death (9–12).

69

Although much work has been done exploring the potential virologic and immunologic factors 70 71 driving Long COVID, the evaluation of autoantibodies in this condition has been more limited. 72 Measurement of anti-nuclear antibodies on standard clinical tests has yielded mixed findings, with 73 some studies identifying a high prevalence of antinuclear antibodies (ANAs) among those with 74 Long COVID (13–15) and other studies finding low prevalence consistent with ANA positivity in the general population (16–18). Although perturbations in interferon signaling pathways have been 75 76 suggested as one potential mechanism of Long COVID (4, 15), anti-interferon antibodies have not been identified in most individuals outside of those who had severe acute infection (16). This is 77

consistent with other post-acute sequelae of COVID such as multisystem inflammatory syndrome

in children (MIS-C), which also has no association with anti-interferon antibodies (19).

80

- The identification of previously reported autoantibodies can be performed using targeted assays. However, identifying the full range of novel autoreactive antibodies, whether they are pathological or not, requires technologies capable of high-throughput, unbiased, proteome-wide screens. In this study, we screened a cohort of individuals with prior SARS-CoV-2 infection, many of whom met clinical criteria for Long COVID, to determine whether a consistent pattern of autoreactivity could be identified. This same technology has been previously utilized to discover novel autoantibodies in a wide range of disease contexts (20–23).
- 88

89 **RESULTS**

90 Distinct set of autoreactive antibodies in individuals with prior SARS-CoV-2 infection 91 We employed a previously published proteome-wide approach using a T7 phage-display assay 92 with immunoprecipitation and next-generation sequencing (PhiP-Seq) (20-24). We tested sera 93 from 185 otherwise healthy individuals with prior SARS-CoV-2 infection in parallel to sera from 57 94 otherwise healthy individuals collected prior to the known existence of COVID-19 (pre-COVID). 95 Using an unbiased analysis, we identified a distinct pattern of autoreactivity which effectively 96 classifies individuals with prior SARS-CoV-2 infection from individuals not yet exposed to the virus 97 with a logistic regression AUC of 0.90 (Figure 1A). The protein targets from which these enriched 98 immunoprecipitated peptides were derived are widely varied and lack any apparent shared 99 biological functions or cell type (Figure 1B). Among the identified targets, a single peptide derived from ARHGAP31 (Figure 2A) displayed the greatest amount of enrichment with 22% of individuals 100 101 with prior SARS-CoV-2 infection yielding enrichment greater than 6 standard deviations of the

102 mean of the pre-COVID controls. No difference in enrichment was observed for those diagnosed

103 with Long COVID with respect to Post-COVID (Figure 2B).

104

To investigate whether the ARHGAP31 peptide enrichment could be the result of cross-reactivity
with antibodies directed against SARS-CoV-2 proteins, we performed a multiple sequence
alignment of this 49-amino acid fragment against the full SARS-CoV-2 proteome. A region within
the SARS-CoV2 Orf1a polyprotein was identified with considerable physico-chemical similarity to
a portion of the autoreactive fragment in ARHGAP31(Jalview Version 2;Figure 2C), supporting the
notion that the observed human peptidome peptide enrichments in post-COVID samples are being
driven by anti-SARS-CoV-2 antibodies.

113 ARHGAP31 is most highly expressed in neuronal cells, Langerhans cells, and endothelial cells

(Human Protein Atlas, proteinatlas.org). We were unable to identify any clinical differences
between individuals with and without ARHGAP31 autoreactivity, such as differences in frequency
of neurologic symptoms.

117

118 Post-COVID autoreactivities are not enriched in individuals with Long COVID

119 To assess whether autoreactive antibodies present in individuals following SARS-CoV-2 infection 120 are associated with Long COVID, we compared the distribution of the enriched post-COVID 121 peptides amongst the 121 individuals with Long COVID and the 64 individuals with prior SARS-CoV-2 infection but without Long COVID (Convalescent COVID). The 20 most enriched proteins 122 123 with at least 5-fold greater than background (defined as fold-change over mock-IP with protein 124 A/G beads) were compared (Figure 3). Seventeen of the 20 enriched proteins were present in 125 both Long COVID and Convalescent COVID, and none of these enrichments was observed in any 126 of the pre-COVID controls. Overall, there was no significant differences in enrichment between

Long COVID and Convalescent COVID. Peptides derived from three proteins, TMED10, FUCA1,
and POL2RK, were only observed in Long COVID, however these were infrequently observed.

129

Subgroup analyses were performed to determine whether any of these observed autoreactivities 130 were enriched in particular symptom-defined phenotypes of Long COVID. These include 131 132 cardiopulmonary (cough, shortness of breath, chest pain, palpitations, and fainting), central 133 neurologic symptoms (problems with vision, headache, difficulty with concentration or memory, 134 dizziness, and difficulty with balance), any neurologic symptom (problems with vision, headache, 135 difficulty with concentration or memory, dizziness, difficulty with balance, trouble with smell or 136 taste, phantosmia, or paresthesia), gastrointestinal (diarrhea, constipation, nausea, vomiting, loss 137 of appetite, and abdominal pain), musculoskeletal (back pain, muscle pain, pain in the arms, legs, 138 or joints), and upper respiratory (runny nose and sore throat).

139

The peptide enrichments from individuals with particular Long COVID phenotypes were compared 140 141 to the enrichments from individuals with Convalescent COVID (no Long COVID symptoms) using 142 a one-sided Kolmogorov-Smirnov test. None of the top 20 autoantibodies were enriched in severe 143 Long COVID, and only 3 autoantibodies were statistically increased in any phenotype: TTF2 and 144 KDM3B in those with cardiopulmonary symptoms and FUCA1 in those with upper respiratory 145 symptoms (Figure 4A). However, using a strict cutoff of 6 standard deviations above the pre-146 COVID controls to determine positivity, none of these autoantibodies was phenotype specific. By 147 looking at the distribution of these antibodies in Long COVID patients with given sub-phenotype 148 relative to the remaining Long COVID patients and all convalescent COVID patients, it was 149 apparent that the statistical significance in a particular phenotype was driven by either a single 150 individual with extremely high autoantibody signal in the case of KDM3B and TTF2, or higher group signal but not meeting the positive threshold cutoff in the case of FUCA1 (Figure 4B). 151

152 Absence of Long COVID specific autoreactivities

153 In addition to analyzing the distribution of post-COVID autoreactive peptide enrichments, we also 154 performed additional analyses to detect those enrichments which might be present only in Long COVID or particular subcategories of Long COVID. To feature-weight enriched peptides, we 155 applied logistic regressions to the degree of enrichment for each individual with Long COVID and 156 157 each individual Long COVID symptom phenotype versus enrichment from convalescent COVID patients who did not have the particular symptoms. We included all previously discussed symptom 158 159 phenotypes, as well as individuals with difficulty concentrating, worsened quality of life, new depression, and generalized anxiety disorder. We were unable to identify a set of enriched 160 161 proteins specific to any of these groups of patients which could effectively distinguish the cohort 162 from controls, as the best receiver operating characteristic (ROC) area under the curve (AUC) was 163 0.67, and the mean AUC was 0.44 (Supplement 1).

164

165 **DISCUSSION**

166 Autoimmunity has been proposed as one potential mechanism driving Long COVID. We applied 167 an unbiased, proteome-wide, validated approach to assess associations between antibody 168 autoreactivity and clinical phenotype. A clear and robust difference in autoreactivity was detected between those infected with SARS-CoV-2 and pre-COVID controls. This difference was 169 170 constituted by peptides from diverse and varied proteins, most of which are intracellular, 171 suggesting that the origin of the differential enrichment is due to cross-reactivity with SARS-CoV-2 172 directed antibodies in those that were exposed. A sequence comparison between a peptide from 173 the most enriched protein, ARHGAP31, and Orf1a of SARS-CoV-2 supports this notion, but 174 orthogonal validation through fine-scale epitope mapping and antibody cloning would be required 175 to demonstrate this conclusively. While the clinical significance of incidental autoreactivity due to 176 the humoral immune response to SARS-CoV-2 remains largely unknown, prior studies have

identified cross reactive autoantibodies in severe sequelae of SARS-CoV-2 infection, including
those that develop severe neurological symptoms (Song et al., 2021). Understanding the clinical
consequences of SARS-CoV-2 driven autoreactivity deserves further attention, perhaps through
long-term longitudinal studies.

181

We found no association to support the hypothesis that autoreactivity, as detected in this assay, contributes to Long COVID. Despite numerous successes, PhIP-seq possesses a number of limitations. Because the T7 phage displayed peptides are only 49 amino acids, the assay inherently detects mostly linear epitopes. Therefore, complex conformational, post translationally modified, or multimeric protein configurations are not predicted to be detectable by this assay, and thus these results do not completely rule out autoimmune interactions in Long COVID that are beyond the scope of PhIP-seq.

189

In addition, our classification of Long COVID and its symptom phenotypes was based exclusively on participant self-report of symptoms. It is possible that future analyses in more homogenous cohorts, particularly those with objectively measured physiologic perturbations now associated with certain Long COVID phenotypes (e.g., postural orthostasis/tachycardia, neurocognitive function deficits, abnormalities on cardiopulmonary exercise testing) may yet reveal a role of autoantibodies in at least a subset of individuals experiencing Long COVID.

196

Long COVID remains a complex clinical entity. Its causes are likely multifactorial, and there is growing consensus that different phenotypes are driven by different pathophysiologic mechanisms (2, 3). Additional work characterizing SARS-CoV-2 specific and autoreactive immune responses in large, well-characterized cohorts over time, during both the acute and post-acute phases of the illness, will be necessary to delineate the biology of Long COVID and other post-acute sequelae of

- 202 SARS-CoV-2 infection, and to lead to the development of potential interventions to treat the
- 203 millions of individuals currently affected by this condition.
- 204

205 METHODS

206 Study participants and measurements

207 Participants were volunteers in the UCSF Long-term Impact of Infection with Novel Coronavirus (LIINC) study (NCT04362150). The details of study design and measurement have been reported 208 209 previously (25). For the current analysis, we included 186 individuals with a history of nucleic acidconfirmed SARS-CoV-2 infection who had a plasma sample collected between 60 and 240 days 210 211 following initial symptom onset or, if asymptomatic, first positive SARS-CoV-2 test. Long COVID 212 was defined using study instruments, which have been described in detail elsewhere (25). Briefly, 213 each participant was queried regarding the presence, severity, and duration of 32 physical and 214 mental health symptoms and quality of life. Details of their medical history and COVID-19 infection 215 and vaccination and treatment history were also recorded. Symptoms that pre-dated SARS-CoV-2 216 infection and that were not changed following infection, as well as those obviously attributed to 217 another cause (e.g. ankle fracture), were not considered to represent Long COVID. All samples 218 included were collected prior to the subject ever receiving a SARS-CoV-2 vaccine.

219

Because of challenges in objectively defining Long COVID and to thoroughly explore the data in
an unbiased manner, we utilized a number of predefined case definitions in our analysis. We
constructed case definitions based on symptom presentation and quality-of-life (QOL) responses.
Symptoms case definitions include: the presence of any new or worsening symptoms since
SARS-CoV-2 infection (Long COVID); presence of 5 or more symptoms (severe Long COVID);
specific symptom groups according to organ system involvement or phenotypic cluster; and
individual symptoms when at least 25 individuals experienced the symptom. For individual and

grouped symptom outcomes, we developed 3 potential comparisons between the symptomatic group and (1) all individuals who reported absence of the symptoms of interest, regardless of Long COVID status (2) only individuals who were consistently asymptomatic and (3) individuals with Long COVID but not the symptoms of interest. Severe Long COVID was compared only to those without any reported symptoms.

232

233 We defined 6 groups of symptoms (symptom phenotypes) based on either organ system cluster. 234 These include cardiopulmonary (cough, shortness of breath, chest pain, palpitations, and fainting), CNS-specific (problems with vision, headache, difficulty with concentration or memory, dizziness, 235 236 and difficulty with balance), any neurologic symptom (problems with vision, headache, difficulty 237 with concentration or memory, dizziness, difficulty with balance, trouble with smell or taste, 238 phantosmia, or paresthesia), gastrointestinal (diarrhea, constipation, nausea, vomiting, loss of 239 appetite, and abdominal pain), musculoskeletal (back pain, muscle pain, pain in the arms, legs, or 240 joints), and upper respiratory (runny nose and sore throat).

241

242 Quality-of-life was assessed using the EuroQol-5D (EQ-5D). Patient Health Questionnaire 243 depression scale (PHQ-8), and Generalized Anxiety Disorder scale (GAD-7). Individuals with 244 Long COVID and the lowest overall quality-of-life (QOL) score measured via the visual analogue 245 scale of the EQ-5D were compared to individuals with the highest overall QOL scores among 246 those with and without Long COVID. Individuals with responses categorized as "moderate 247 depression" on the PHQ-8 (score higher than 10) and "moderate anxiety" on the GAD-7 (score 248 higher than 9) were compared to all participants with scores indicating less severe classifications 249 than "moderate depression" and "moderate anxiety" in the following groups: (1) all participants 250 regardless of Long COVID status (2) all participant without Long COVID and (3) all participants 251 with Long COVID.

- 252 In addition, we recently demonstrated associations between Long COVID and other chronic latent
- viral infections, including serologic evidence suggesting recent Epstein-Barr virus (EBV)
- reactivation (26). For this reason, we also used binary variables to create groups indicating the
- 255 presence of this condition.
- 256

257 Biospecimen collection

At each visit, whole blood was collected in EDTA tubes. Plasma was isolated and stored in -80F until the time of analysis.

260

261 Phage Immunoprecipitation and Sequencing (PhIP-Seq)

262 PhIP-Seq was performed following our previously published vacuum-based PhIP-Seq protocol

263 (23) (https://www.protocols.io/view/scaled-high-throughput-vacuum-phip-protocol-

264 ewov1459kvr2/v1).

265

266 PhIP-Seq analysis

All analysis (except when specifically stated otherwise) was performed at the gene-level, in which 267 268 all reads for all peptides mapping to the same gene were summed, and 0.5 reads were added to each gene to allow inclusion of genes with zero reads in mathematical analyses. Within each 269 270 individual sample, reads were normalized by converting to the percentage of total reads. To 271 normalize each sample against background non-specific binding, a fold-change(FC) over mock-IP was calculated by dividing the sample read percentage for each gene by the mean read-272 273 percentage of the same gene for the AG bead only controls. This FC signal was then used for side-by-side comparison between samples and cohorts. Samples which had a FC of 5 or greater 274 275 were considered enriched for an antibody, and samples with a FC of 6 standard deviations above 276 the mean of pre-COVID controls were considered positive for an autoantibody. FC values were

also used to calculate z-scores for each disease category sample by using each respective control
(as specified in figures and results), and for each control sample by using all remaining controls.
These z-scores were used for the logistic-regression feature weighting. In the case peptide-level
analysis, raw reads were normalized by calculating the number of reads per 100,000 reads.

282 Statistical methods

All statistical analysis was performed in Python using the Scipy Stats package. A two-way

Kolmogorov-Smirnoff(KS) test was used for comparisons of FC PhIP-Seq data between groups of

samples, except in the case of specifically looking for those genes with increased signal only in

the disease-cohort in which a one-way KS test was employed. The logistic regression machine-

learning classifiers were performed using our recently described methods (23). Utilizing the Scikit-

learn package, logistic regression classifiers were applied to z-scored PhIP-Seq values from

individuals with a designated disease category versus the designated control. A liblinear solver

was used with L1 regularization, and the model was evaluated using a five-fold cross-validation (4

of the 5 for training, 1 of the 5 for testing).

292

293 Informed consent

Participants provided written informed consent. The study was approved by the UCSF InstitutionalReview Board.

296

297 FOOTNOTES

298 Acknowledgements

299 We are grateful to the study participants and their medical providers. We acknowledge current and

300 former LIINC clinical study team members Tamara Abualhsan, Andrea Alvarez, Khamal Anglin,

301 Urania Argueta, Mireya Arreguin, Kofi Asare, Melissa Buitrago, Monika Deswal, Nicole DelCastillo,

Emily Fehrman, Halle Grebe, Heather Hartig, Yanel Hernandez, Rebecca Hoh, Beatrice Huang, 302 303 Marian Kerbleski, Raushun Kirtikar, James Lombardo, Monica Lopez, Michael Luna, Sadie Munter, Lynn Ngo, Enrique Martinez Ortiz, Antonio Rodriguez, Justin Romero, Dylan Ryder, Ruth 304 Diaz Sanchez, Matthew So, Celina Song, Viva Tai, Alex Tang, Cassandra Thanh, Fatima Ticas, 305 Leonel Torres, Brandon Tran, Daisy Valdivieso, Deepshika Varma, and Meghann Williams; and 306 307 LIINC laboratory team members Amanda Buck, Tyler-Marie Deveau, Joanna Donatelli, Jill Hakim, Nikita Iyer, Owen Janson, Brian LaFranchi, Christopher Nixon, Isaac Thomas, and Keirstinne 308 309 Turcios. We thank Jessica Chen, Aidan Donovan, Carrie Forman, and Rania Ibrahim for assistance with data entry and review. We thank the UCSF AIDS Specimen Bank for processing 310 311 specimens and maintaining the LIINC biospecimen repository. We are grateful to Elnaz Eilkhani 312 and Monika Deswal for regulatory support.

313

314 Author Contributions

AB, ST, BG, JDT, JNM, SGD, TJH, JLD, and MJP designed the study. JDT, JNM, SGD, TJH, and 315 316 MJP designed and oversaw the LIINC cohort, with major contributions from BG, MSD, PYH, and 317 JH. KA, BH, and RH managed cohort operations. Clinical data were collected by JR, BT, RK, HG, 318 and MS. SL and SG managed the data and developed the clinical dataset. ST, SL, SG, and MJP selected participants for inclusion in this study. Biospecimens were processed in the laboratories 319 of BG and TJH. CW, AS, and AM performed the measurements in the laboratories of MSA and 320 321 JLD. AB performed the data analysis. AB, TJH, JLD, and MJP wrote the first draft of the paper, 322 with input from all other authors. All authors edited the manuscript and approved the final version. 323

324 Funding

325 This work was supported by NIH/NIAID 3R01AI141003-03S1 and NIH/NIAID R01AI158013 (to M

326 Gandhi and M Spinelli), Pediatric Scientist Development Program and the Eunice Kennedy

- 327 Shriver National Institute of Child Health and Human Development (K12-HD000850 to A.
- Bodansky), and Chan Zuckerberg Biohub support for J. DeRisi.
- 329

330 Conflicts of Interest

- TJH reports grants from Merck & Co, Gilead Sciences, and Bristol-Myers Squibb, and has
- 332 provided consulting for Roche, outside the submitted work. SGD reports grants and/or personal
- 333 fees from Gilead Sciences, Merck & Co., Viiv, AbbVie, Eli Lilly, ByroLogyx, and Enochian
- Biosciences, outside the submitted work. JD reports paid compensation for consulting for the
- 335 Public Health Company and Allen & Co. MJP reports consulting fees from Gilead Sciences and
- 336 AstraZeneca, outside the submitted work. All other authors report no potential conflicts.

337

339 FIGURE LEGENDS

- 340 Figure 1: PhIP-Seq autoreactivities distinguish post-COVID sera from pre-COVID controls.
- 341 Logistic regression comparing PhIP-Seq autoreactivities in all individuals with prior COVID
- 342 infection compared to pre-COVID controls. Barplot showing autoreactivities with the top 20 logistic
- 343 regression coefficients.
- 344
- Figure 2: Post-COVID anti-ARHGAP31 autoreactivities target specific region with similarity
 to SARS-CoV-2
- 347 (A) Stripplots showing distribution of ARHGAP31 autoreactivities in Long COVID, individuals with
- 348 prior COVID infection but without Long COVID, and pre-COVID controls. Dotted line at 6 standard
- 349 deviations above mean of pre-COVID controls. (B) Distribution of anti-ARHGAP31 autoreactivity
- 350 signal within ARHGAP31 full length protein. One specific fragment is targeted. (C) Amino-acid
- 351 sequence of the autoreactive region of ARHGAP31 and amino-acid sequence of a region of
- 352 SARS-CoV-2 Orf1a with similarity. Shown below is the multiple sequence
- 353 alignment(ClustalOmega; asterisk=identical amino acid; colon=strongly similar properties with
- 354 Gonnet PAM 250 matrix score >0.5; period=weakly similar with Gonnet PAM 250 matrix score
- between 0 and 0,5) and strong physical-chemical conservation (JalView; amino acid physical-
- 356 chemical conservation scored on a scale of 1-11, Asterisk=score of 11 and identical amino acid,
- 357 Plus=10, all properties conserved).
- 358

Figure 3: Post-COVID autoreactivities are similarly distributed among Long COVID and controls.

Hierarchically clustered (Pearson) heatmaps showing the PhIP-Seq enrichment for the top 20
 autoreactivities ranked by logistic regression coefficient in each Long COVID patient, each COVID
 convalescent patient, and each pre-COVID control.

364	Figure 4: Few significantly increased autoreactivities in Long COVID symptom phenotypes	
365	(A) Heatmap with p-values (Kolmogorov-Smirnov testing) of differences in autoantigen enrichmer	
366	for all individuals with prior COVID infection with and without additional clinical factors. Top-row	
367	compares those with and without Long COVID. Lower rows show subcategories of Long COVID.	
368	(B) Stripplots showing the three autoantibodies with statistically significant enrichment in a post-	
369	COVID clinical phenotype. Dotted-lines show 6 standard-deviations above the mean of pre-	
370	COVID signal.	
371		
372	Supplement 1: PhIP-Seq is unable to distinguish Long COVID symptom phenotypes from	
373	controls.	
374	(A)Logistic regression receiver operating characteristic (ROC) curves for Long COVID patients	
375	with different specified symptom phenotypes relative to patients previously infected with COVID	
376	without the phenotype, or (B) with and without EBV laboratory findings.	

377

379 **REFERENCES**

- 1. Nalbandian A et al. Post-acute COVID-19 syndrome [Internet]. Nat. Med. [published online]
- 381 ahead of print: March 22, 2021]; doi:10.1038/s41591-021-01283-z
- 382 2. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and
- 383 recommendations. *Nat. Rev. Microbiol.* 2023;1–14.
- 384 3. Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. *Trends*385 *Immunol.* 2022;43(4):268–270.
- 386 4. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An
- 387 Overview of Biological Factors That May Contribute to Persistent Symptoms [Internet]. *Frontiers in*
- 388 *Microbiology* 2021;12. doi:10.3389/fmicb.2021.698169
- 389 5. Peluso MJ, Donatelli J, Henrich TJ. Long-term immunologic effects of SARS-CoV-2 infection:
- 390 leveraging translational research methodology to address emerging questions. *Transl. Res.*

391 2022;241:1–12.

- 392 6. Zuo Y et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
- 393 [Internet]. Sci. Transl. Med. 2020;12(570). doi:10.1126/scitranslmed.abd3876
- 7. Chang SE et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. *Nat. Commun.* 2021;12(1):5417.
- 396 8. Woodruff MC et al. Dysregulated naïve B cells and de novo autoreactivity in severe COVID-19
- 397 [Internet]. *Nature* [published online ahead of print: August 31, 2022]; doi:10.1038/s41586-022-

398 05273-0

399 9. Bastard P et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

400 [Internet]. *Science* 2020;370(6515). doi:10.1126/science.abd4585

- 401 10. Bastard P et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected
- 402 individuals over 70 years old and account for ~20% of COVID-19 deaths [Internet]. Sci Immunol
- 403 2021;6(62). doi:10.1126/sciimmunol.abl4340
- 404 11. Vazquez SE et al. Neutralizing Autoantibodies to Type I Interferons in COVID-19
- 405 Convalescent Donor Plasma. J. Clin. Immunol. 2021;41(6):1169–1171.
- 406 12. van der Wijst MGP et al. Type I interferon autoantibodies are associated with systemic
- 407 immune alterations in patients with COVID-19. Sci. Transl. Med. 2021;13(612):eabh2624.
- 408 13. Son K et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID
- 409 symptoms [Internet]. Eur. Respir. J. [published online ahead of print: September 22, 2022];
- 410 doi:10.1183/13993003.00970-2022
- 411 14. Seeßle J et al. Persistent symptoms in adult patients one year after COVID-19: a prospective
- 412 cohort study [Internet]. *Clin. Infect. Dis.* [published online ahead of print: July 5, 2021];
- 413 doi:10.1093/cid/ciab611
- 414 15. Su Y et al. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae [Internet]. *Cell*415 2022;0(0). doi:10.1016/j.cell.2022.01.014
- 416 16. Peluso MJ, Thomas IJ, Munter SE, Deeks SG, Henrich TJ. Lack of Antinuclear Antibodies in
 417 Convalescent Coronavirus Disease 2019 Patients With Persistent Symptoms. *Clin. Infect. Dis.*418 2022;74(11):2083–2084.
- 419 17. Schultheiß C et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute
 420 sequelae of COVID-19. *Cell Rep Med* 2022;3(6):100663.

- 421 18. Klein J et al. Distinguishing features of Long COVID identified through immune profiling
- 422 [Internet]. *medRxiv* [published online ahead of print: August 10, 2022];
- 423 doi:10.1101/2022.08.09.22278592
- 424 19. Bodansky A et al. NFKB2 haploinsufficiency identified via screening for IFNα2 autoantibodies
- in children and adolescents hospitalized with SARS-CoV-2-related complications [Internet]. J.
- 426 Allergy Clin. Immunol. [published online ahead of print: December 9, 2022];
- 427 doi:10.1016/j.jaci.2022.11.020
- 428 20. Mandel-Brehm C et al. Kelch-like Protein 11 Antibodies in Seminoma-Associated
- 429 Paraneoplastic Encephalitis. N. Engl. J. Med. 2019;381(1):47–54.
- 430 21. O'Donovan B et al. High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by
- 431 programmable phage display. *Brain Commun* 2020;2(2):fcaa059.
- 432 22. Vazquez SE et al. Identification of novel, clinically correlated autoantigens in the monogenic
- 433 autoimmune syndrome APS1 by proteome-wide PhIP-Seq [Internet]. *Elife* 2020;9.
- 434 doi:10.7554/eLife.55053
- 435 23. Vazquez SE et al. Autoantibody discovery across monogenic, acquired, and COVID-19-

436 associated autoimmunity with scalable PhIP-seq [Internet]. *Elife* 2022;11. doi:10.7554/eLife.78550


437 24. Larman HB et al. Autoantigen discovery with a synthetic human peptidome. *Nat. Biotechnol.*438 2011;29(6):535–541.


439 25. Peluso MJ et al. Persistence, magnitude, and patterns of postacute symptoms and quality of


440 life following onset of SARS-CoV-2 infection: cohort description and approaches for measurement.


- 441 In: Open forum infectious diseases. Oxford University Press US; 2022:ofab640
- 442 26. Peluso MJ et al. Impact of pre-existing chronic viral infection and reactivation on the


- 443 development of long COVID [Internet]. J. Clin. Invest. [published online ahead of print: December
- 444 1, 2022]; doi:10.1172/JCI163669











В